Literature DB >> 25908586

G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.

Saurabh Agarwal1, Anna Lakoma2, Zaowen Chen1, John Hicks3, Leonid S Metelitsa1, Eugene S Kim4, Jason M Shohet5.   

Abstract

Increasing evidence suggests that inflammatory cytokines play a critical role in tumor initiation and progression. A cancer stem cell (CSC)-like subpopulation in neuroblastoma is known to be marked by expression of the G-CSF receptor (G-CSFR). Here, we report on the mechanistic contributions of the G-CSFR in neuroblastoma CSCs. Specifically, we demonstrate that the receptor ligand G-CSF selectively activates STAT3 within neuroblastoma CSC subpopulations, promoting their expansion in vitro and in vivo. Exogenous G-CSF enhances tumor growth and metastasis in human xenograft and murine neuroblastoma tumor models. In response to G-CSF, STAT3 acts in a feed-forward loop to transcriptionally activate the G-CSFR and sustain neuroblastoma CSCs. Blockade of this G-CSF-STAT3 signaling loop with either anti-G-CSF antibody or STAT3 inhibitor depleted the CSC subpopulation within tumors, driving correlated tumor growth inhibition, decreased metastasis, and increased chemosensitivity. Taken together, our results define G-CSF as a CSC-activating factor in neuroblastoma, suggest a comprehensive reevaluation of the clinical use of G-CSF in these patients to support white blood cell counts, and suggest that direct targeting of the G-CSF-STAT3 signaling represents a novel therapeutic approach for neuroblastoma. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25908586      PMCID: PMC4470771          DOI: 10.1158/0008-5472.CAN-14-2946

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.

Authors:  Edmond Chipumuro; Eugenio Marco; Camilla L Christensen; Nicholas Kwiatkowski; Tinghu Zhang; Clark M Hatheway; Brian J Abraham; Bandana Sharma; Caleb Yeung; Abigail Altabef; Antonio Perez-Atayde; Kwok-Kin Wong; Guo-Cheng Yuan; Nathanael S Gray; Richard A Young; Rani E George
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

2.  Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Authors:  Tom Van Maerken; Liesbeth Ferdinande; Jasmien Taildeman; Irina Lambertz; Nurten Yigit; Liesbeth Vercruysse; Ali Rihani; Martin Michaelis; Jindrich Cinatl; Claude A Cuvelier; Jean-Christophe Marine; Anne De Paepe; Marc Bracke; Frank Speleman; Jo Vandesompele
Journal:  J Natl Cancer Inst       Date:  2009-11-10       Impact factor: 13.506

3.  Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells.

Authors:  Seog-Young Kim; Jin Wook Kang; Xinxin Song; Bo Kyoung Kim; Young Dong Yoo; Yong Tae Kwon; Yong J Lee
Journal:  Cell Signal       Date:  2013-01-16       Impact factor: 4.315

4.  Jak/Stat3 signaling promotes somatic cell reprogramming by epigenetic regulation.

Authors:  Yong Tang; Yan Luo; Zongliang Jiang; Yinghong Ma; Chih-Jen Lin; Chul Kim; Mark G Carter; Tomokazu Amano; Joonghong Park; Sharon Kish; Xiuchun Cindy Tian
Journal:  Stem Cells       Date:  2012-12       Impact factor: 6.277

5.  The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice.

Authors:  Kai Diederich; Sevgi Sevimli; Henrike Dörr; Evelin Kösters; Maike Hoppen; Lars Lewejohann; Rainer Klocke; Jens Minnerup; Stefan Knecht; Sigrid Nikol; Norbert Sachser; Armin Schneider; Ali Gorji; Clemens Sommer; Wolf-Rüdiger Schäbitz
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

6.  STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer.

Authors:  Wei Wei; David J Tweardy; Mei Zhang; Xiaomei Zhang; John Landua; Ivana Petrovic; Wen Bu; Kevin Roarty; Susan G Hilsenbeck; Jeffrey M Rosen; Michael T Lewis
Journal:  Stem Cells       Date:  2014-10       Impact factor: 6.277

7.  Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Authors:  Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

8.  Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D.

Authors:  Sandra Baumgart; Nai-Ming Chen; Jens T Siveke; Alexander König; Jin-San Zhang; Shiv K Singh; Elmar Wolf; Marek Bartkuhn; Irene Esposito; Elisabeth Heßmann; Johanna Reinecke; Julius Nikorowitsch; Marius Brunner; Garima Singh; Martin E Fernandez-Zapico; Thomas Smyrk; William R Bamlet; Martin Eilers; Albrecht Neesse; Thomas M Gress; Daniel D Billadeau; David Tuveson; Raul Urrutia; Volker Ellenrieder
Journal:  Cancer Discov       Date:  2014-04-02       Impact factor: 39.397

Review 9.  Epithelial to mesenchymal transition: new and old insights from the classical neural crest model.

Authors:  Pablo H Strobl-Mazzulla; Marianne E Bronner
Journal:  Semin Cancer Biol       Date:  2012-04-30       Impact factor: 15.707

10.  Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.

Authors:  Jeremy D Waight; Qiang Hu; Austin Miller; Song Liu; Scott I Abrams
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

View more
  39 in total

1.  Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.

Authors:  Veronica Lifshitz; Saul J Priceman; Wenzhao Li; Gregory Cherryholmes; Heehyoung Lee; Adar Makovski-Silverstein; Lucia Borriello; Yves A DeClerck; Hua Yu
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261

2.  Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity.

Authors:  Seiichi Odate; Veronica Veschi; Shuang Yan; Norris Lam; Richard Woessner; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2016-10-19       Impact factor: 12.531

Review 3.  Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options.

Authors:  Veronica Veschi; Francesco Verona; Carol J Thiele
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

4.  Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.

Authors:  Sarah B Whittle; Valeria Smith; Allison Silverstein; Margaret Parmeter; Charles G Minard; M Brooke Bernhardt; Peter E Zage; Rajkumar Venkatramani; Jed G Nuchtern; Andras Heczey; Heidi V Russell; Jason M Shohet; Jennifer H Foster
Journal:  Pediatr Blood Cancer       Date:  2020-07-30       Impact factor: 3.167

5.  Novel K6-K14 keratin fusion enhances cancer stemness and aggressiveness in oral squamous cell carcinoma.

Authors:  Fuu-Jen Tsai; Ming-Tsung Lai; Jack Cheng; Stev Chun-Chin Chao; Praveen Kumar Korla; Hui-Jye Chen; Chung-Ming Lin; Ming-Hsui Tsai; Chun-Hung Hua; Chia-Ing Jan; Natini Jinawath; Chia-Chen Wu; Chih-Mei Chen; Brian Yu-Ting Kuo; Li-Wen Chen; Jacky Yang; Tritium Hwang; Jim Jinn-Chyuan Sheu
Journal:  Oncogene       Date:  2019-03-13       Impact factor: 9.867

6.  G-CSF partially mediates effects of sleeve gastrectomy on the bone marrow niche.

Authors:  Ziru Li; Julie Hardij; Simon S Evers; Chelsea R Hutch; Sarah M Choi; Yikai Shao; Brian S Learman; Kenneth T Lewis; Rebecca L Schill; Hiroyuki Mori; Devika P Bagchi; Steven M Romanelli; Ki-Suk Kim; Emily Bowers; Cameron Griffin; Randy J Seeley; Kanakadurga Singer; Darleen A Sandoval; Clifford J Rosen; Ormond A MacDougald
Journal:  J Clin Invest       Date:  2019-05-06       Impact factor: 14.808

7.  Notch1-STAT3-ETBR signaling in brain injury and cancer.

Authors:  Matthew D LeComte; Jeffrey L Spees
Journal:  Cytokine       Date:  2015-08-25       Impact factor: 3.861

8.  G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Response.

Authors:  Eugene S Kim; Saurabh Agarwal; Jason M Shohet
Journal:  Cancer Res       Date:  2015-09-03       Impact factor: 12.701

Review 9.  The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression.

Authors:  Belinda Yeo; Andrew D Redfern; Kellie A Mouchemore; John A Hamilton; Robin L Anderson
Journal:  Clin Exp Metastasis       Date:  2018-07-02       Impact factor: 5.150

10.  G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

Authors:  Paula Martinez Sanz; Dieke J van Rees; Hanke L Matlung; Godelieve A M Tytgat; Katka Franke; Lieke M J van Zogchel; Bart Klein; Panagiota Bouti; Hugo Olsman; Karin Schornagel; Ivana Kok; Ali Sunak; Kira Leeuwenburg; Ilse Timmerman; Miranda P Dierselhuis; Waleed M Kholosy; Jan J Molenaar; Robin van Bruggen; Timo K van den Berg; Taco W Kuijpers
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.